THE SPECIFIC SERUM TREATMENT OF PNEUMOCOCCUS TYPE II PNEUMONIA
- 25 February 1933
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 100 (8) , 560-566
- https://doi.org/10.1001/jama.1933.02740080024006
Abstract
The clinical entity "lobar pneumonia" is gradually coming to be recognized as comprising a group of specific infectious diseases.1This is due primarily to the interest aroused by the serologic classification of the pneumococci and the elaboration of specific therapeutic serums against two of the most frequent of these types, namely, types I and II. The beneficial effects of specific antipneumococcic serum in the treatment of pneumonia due to the type I pneumococcus have been repeatedly demonstrated. In pneumonia due to this type, the death rate has been reduced by one half,2and rapid symptomatic improvement has been observed3in cases treated early in the disease. The type II pneumococcus occupies an important place in the etiology of lobar pneumonia. It causes between 134and 235per cent of all pneumococcic pneumonias with a mortality, in non-serum treated cases, of from 302bto 46Keywords
This publication has 0 references indexed in Scilit: